Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...

After a small-cap fund took first last quarter, large-cap growth funds rode most of the “Magnificent Seven” to dominate the ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announced that approval has been received from an independent review board, for human pilot study #3 (the "Study"), ...

Fourteen years ago, the older drug cousin of semaglutide (Ozempic and Wegovy) came onto the market. The drug, liraglutide, is ...

Cramer remains steadfast on Eli Lilly and Company (NYSE:LLY) as per Mad Money’s episode on September 30. Despite there being ...

Fourteen years ago, the older drug cousin of semaglutide (Ozempic and Wegovy) came onto the market. The drug, liraglutide, is ...

"God knows what volume they're actually selling. And who knows? You're just taking it," one expert told The Post.

And what better place to find dominant companies with decades-long growth opportunities than in healthcare? Healthcare isn't ...

In this article, we will discuss: 12 Best Growth Stocks To Buy According To Hedge Funds.